CPRC
GILD icon

Consolidated Portfolio Review Corp’s Gilead Sciences GILD Stock Holding History

Consolidated Portfolio Review Corp’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,645
Closed -$294K – 177
2025
Q3 		$294K Buy
+2,645
New +$301K 0.04% 375

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Consolidated Portfolio Review Corp's GILD Position: Q4 2025 in Review

Consolidated Portfolio Review Corp sold out of Gilead Sciences (GILD) in Q4 2025, closing a stake of 2,645 shares — an estimated $294K sold.

Consolidated Portfolio Review Corp first reported a position in GILD in Q3 2025 and held it in 1 quarter. The position peaked at $294K in Q3 2025. 2,217 funds tracked by Wall St. Rank hold GILD as of Q4 2025.

  • Consolidated Portfolio Review Corp reported no remaining Gilead Sciences position as of Q4 2025 after selling out during the quarter.
  • Consolidated Portfolio Review Corp sold 2,645 Gilead Sciences shares in Q4 2025, an estimated $294K.
  • Consolidated Portfolio Review Corp first reported a position in Gilead Sciences in Q3 2025 and held it in 1 quarter.
  • Consolidated Portfolio Review Corp's Gilead Sciences position peaked at $294K in Q3 2025.
  • 2,217 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2025.

Based on Consolidated Portfolio Review Corp's 13F filing for Q4 2025, filed 26 Jan 2026.